ArticleFrontiers in immunology2026
A multivariable probability score integrating routine immunoassay results for the immunological assessment of antisynthetase syndrome.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accurate detection of anti-aminoacyl-tRNA synthetase autoantibodies (ASA) is central to the diagnosis of antisynthetase syndrome (ASyS). Although immunoprecipitation (IP) remains the historical reference method, its limited availability in routine clinical laboratories necessitates reliance on commercially available immunoassays. The diagnostic performance of these assays varies by specificity and cut-off interpretation. We aimed to improve the post-analytical interpretation of ASA positivity in routine practice. Methods: We conducted a retrospective single-center study including 125 patients with at least one positive ASA detected by line-blot immunoassay (LIA) between January 2023 and September 2025. Thirty-three patients fulfilled clinician-based diagnostic criteria for ASyS, while 92 served as controls. Additional immunological data included indirect immunofluorescence on HEp-2 cells (IIF-HEp-2) and anti-Ro52 autoantibodies. Variables associated with ASyS were incorporated into multivariable logistic regression models. A diagnostic probability score was derived from the final model and evaluated using receiver operating characteristic (ROC) curve analysis. Results: Semi-quantitative LIA intensity alone showed limited discriminatory capacity, particularly in cases with low-intensity bands. In contrast, compatible cytoplasmic IIF-HEp-2 patterns and anti-Ro52 co-positivity significantly improved discrimination. The final multivariable model integrating semi-quantitative LIA intensity, IIF-HEp-2 cytoplasmic pattern (AC-19/20), and anti-Ro52 co-positivity achieved an AUC of 0.94 (95% CI 0.89-0.99). Stratification into low-, intermediate-, and high-probability zones provided clinically interpretable diagnostic categories. Conclusion: In ASA-positive patients, probability-based integration of routinely available immunoassay results improves the interpretation of LIA positivity and enhances discrimination between ASyS and alternative diagnoses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.